🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

RecruitingPhase 3Ages 5 Years - 17 YearsAllBristol-Myers Squibb
NCT06869551 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria * Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). * Participants must have at least three joints that are affected by arthritis. * Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria * Participants must not have been diagnosed with JPsA before 5 years of age. * Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, * Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. * Other protocol-defined Inclusion/Exclusion criteria apply.
💊

What it tests

  • Deucravacitinib
  • Placebo
📍

Where

48 sites
Local Institution - 0038
Lancaster, United States
Local Institution - 0020
Chicago, United States
Local Institution - 0023
Indianapolis, United States
Local Institution - 0059
North New Hyde Park, United States
Local Institution - 0065
Cincinnati, United States
Local Institution - 0066
Cleveland, United States
Local Institution - 0036
Austin, United States
Centro de Oncologia Leonardo Da Vinci - ATO Terapias
Fortaleza, Brazil

…and 40 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy